1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,210 | 3,316 | 09.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | GENFLEET-B Repurchases 135,000 Shares on Thu for HKD3.83 million | 1 | AASTOCKS | ||
| Do | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.09. | GENFLEET-B (02595): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.09. | GENFLEET-B (02595): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 5 | HKEx | ||
| 23.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT DISCLOSURE ARRANGEMENTS FOR CLINICAL DATA FROM STUDIES OF GFH375 AND GFH276 | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.09. | GENFLEET-B (02595): ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES | 2 | HKEx | ||
| 21.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PROGRESS OF SHARE REPURCHASE | 1 | HKEx | ||
| 17.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 16.09. | GENFLEET-B (02595): 2026 INTERIM REPORT | 1 | HKEx | ||
| 15.09. | GENFLEET-B Says GFH375 Achieves 59.2% ORR in Phase II Study for Previously Treated NSCLC | 1 | AASTOCKS | ||
| 15.09. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FAVORABLE PHASE II EFFICACY DATA OF GFH375 (ORAL KRAS G12D INHIBITOR) MONOTHERAPY IN PRETREATED NSCLC PRESENTED ... | 1 | HKEx | ||
| 09.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.09. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375, ORAL KRAS G12D INHIBITOR, ADVANCES INTO A PHASE II STUDY EVALUATING MONOTHERAPY AND COMBINATION REGIMENS ... | 1 | HKEx | ||
| 21.08. | GENFLEET-B (02595): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 20.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 ADVANCES INTO A NOVEL PHASE II STUDY FEATURING TWO FIRST-IN-WORLD COMBINATION THERAPIES FOR PANCREATIC ... | 2 | HKEx | ||
| 10.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT WORLD'S FIRST REGISTRATIONAL PHASE III STUDY FOR ORAL KRAS G12D INHIBITOR IN NSCLC ADVANCES, AS FIRST PATIENT ... | 1 | HKEx | ||
| 06.08. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | +3,69 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | +2,45 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | +1,31 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | +14,12 % | Moderna zeigt, wie schwierig der Sprung von der Studie zum Geschäftsmodell ist - ein Biotech aus Australien macht es vor | ||
| NURIX THERAPEUTICS | 22,350 | +0,63 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | +0,29 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | +2,88 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | +5,59 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | +1,68 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | +3,12 % | $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| ABSCI | 10,165 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,006 (-0,18 %) liegt der Kurs bei 3,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.